ABBV241227C180000
- 1.01
- +0.26+34.67%
AbbVie Newsroom
Piper Sandler has raised AbbVie's Target Price to $220.
AbbVie Analyst Ratings
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $220
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Alcon (ALC) and Humana (HUM)
BofA Securities Maintains AbbVie(ABBV.US) With Hold Rating, Announces Target Price $191
AbbVie Analyst Ratings
B of A Securities Reinstates Neutral on AbbVie, Announces $191 Price Target
Citi Maintains AbbVie(ABBV.US) With Buy Rating
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Protagonist Therapeutics (PTGX)
TD Cowen Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $225
AbbVie: Strong Buy Rating Based on Growth Potential and Strategic Positioning
Positive Outlook for Aldeyra Therapeutics: Buy Rating Backed by Promising Reproxalap Prospects and Strategic Partnership With AbbVie
AbbVie: Resilient Market Position and Growth Potential Justify Buy Rating
Daiwa Securities Downgrades AbbVie to Neutral From Outperform, Adjusts Price Target to $180 From $210
Alector Downgraded to Underperform at BofA After Alzheimer's Trial Miss
AbbVie Analyst Ratings
Leerink Partners Upgrades AbbVie(ABBV.US) to Buy Rating, Announces Target Price $206
Wells Fargo Maintains AbbVie(ABBV.US) With Buy Rating, Cuts Target Price to $195
Wells Fargo Adjusts Price Target on AbbVie to $195 From $205, Maintains Overweight Rating
Redburn Atlantic Adjusts AbbVie's Price Target to $216 From $215, Keeps Buy Rating